Related Experiment Video
Updated: May 5, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumocystis jirovecii Pneumonia in Non-HIV, Non-HCT Adults: Real-World Patterns of Overlapping Immunosuppression and
Daniel B Chastain1, Dustin M Solorzano-Salazar2, Aditya Mantha3
1Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, USA.
Background:
Pneumocystis jirovecii pneumonia (PJP) is increasingly recognized among immunocompromised adults without HIV, yet prophylaxis use remains inconsistent. Data describing cumulative and overlapping immunosuppressive exposures before PJP diagnosis are limited.
Objective:
To characterize immunosuppressive exposure patterns and evaluate use of PJP-active therapy among non-HIV, nonhematopoietic cell transplant (non-HCT) adults with PJP.
Methods:
This retrospective cohort study (2011-2024) used the TriNetX Research Network. Adults without HIV or prior HCT with laboratory-confirmed PJP (positive polymerase chain reaction or antigen from respiratory specimens) were included. Demographics, comorbidities, and exposure to glucocorticoids (GCs), antineoplastics (ANs), and immunosuppressants (ISs) within 90 days before diagnosis were assessed. Overlapping immunosuppressive regimens and their associations with receipt of PJP-active therapy were evaluated. Because prescribing indication and dosing were unavailable, prescriptions for trimethoprim/sulfamethoxazole, atovaquone, dapsone, or pentamidine were grouped as PJP-active therapy, representing prophylactic, preemptive, or empiric use.
Results:
Among 578 adults with PJP, 87% received GCs, 37% ANs, and 26% ISs. More than half (54%) were exposed to 2 or more drug classes, whereas 10% had no identifiable immunosuppressive medication exposure. Despite frequent multidrug immunosuppression, only 32% received PJP-active therapy before diagnosis. GC exposure was more common among patients who received PJP-active therapy (97% vs 82%, P < 0.001), while AN and IS exposures did not differ between groups.
Conclusion And Relevance:
PJP in non-HIV, non-HCT adults commonly occurs in the setting of frequent multidrug immunosuppression. These findings reveal a disconnect between cumulative immunosuppressive risk and prophylaxis practices and support approaches that incorporate overall immunologic burden rather than single-agent thresholds.
More Related Videos
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:29Pneumonia I: Introduction
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: